Aviragen Therapeutics (AVIR) Tops Q2 EPS by 11c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.38), $0.11 better than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• RBC Capital Starts Tabcorp Holdings (TAH:AU) (TABCF) at Outperform
• Endava CFO placed on leave amid accounting probe